Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
In 2023, the State of Idaho launched an ambitious technological overhaul with the Luma system, a comprehensive, cloud-based ...
Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback